An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Sponsor: Hoffmann-La Roche